Jiameng Zhang - Publications
Affiliations: | 2004 | Biostatistics | University of Pennsylvania, Philadelphia, PA, United States |
Year | Citation | Score | |||
---|---|---|---|---|---|
2014 | Zhang J, Waubant E, Cutter G, Wolinsky J, Leppert D. Composite end points to assess delay of disability progression by MS treatments. Multiple Sclerosis Journal. 20: 1494-1501. PMID 24675040 DOI: 10.1177/1352458514527180 | 0.314 | |||
2013 | Zhang J, Waubant E, Cutter G, Wolinsky JS, Glanzman R. EDSS variability before randomization may limit treatment discovery in primary progressive MS. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 775-81. PMID 23027880 DOI: 10.1177/1352458512459685 | 0.312 | |||
2012 | Zhang J, Waubant E, Cutter G, Wolinsky J, Glanzman R. Improvements in the Power of Detecting Treatment Effect in a Primary Progressive Multiple Sclerosis (PPMS) Clinical Trial with the Use of Composite Disability Outcome Endpoints (P01.151) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P01.151 | 0.33 | |||
2009 | Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology. 66: 460-71. PMID 19847908 DOI: 10.1002/Ana.21867 | 0.318 | |||
2007 | Zhang J, Heitjan DF. Impact of nonignorable coarsening on Bayesian inference. Biostatistics (Oxford, England). 8: 722-43. PMID 17215331 DOI: 10.1093/Biostatistics/Kxm001 | 0.501 | |||
2006 | Zhang J, Heitjan DF. A simple local sensitivity analysis tool for nonignorable coarsening: application to dependent censoring. Biometrics. 62: 1260-8. PMID 17156301 DOI: 10.1111/J.1541-0420.2006.00580.X | 0.492 | |||
2005 | Zhang J, Heitjan DF. Nonignorable censoring in randomized clinical trials. Clinical Trials (London, England). 2: 488-96. PMID 16422309 DOI: 10.1191/1740774505Cn128Oa | 0.475 | |||
Show low-probability matches. |